Back to Search
Start Over
Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2022 Mar 01; Vol. 61 (5), pp. 679-685. Date of Electronic Publication: 2021 Aug 31. - Publication Year :
- 2022
-
Abstract
- Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas.
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 61
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 34471015
- Full Text :
- https://doi.org/10.2169/internalmedicine.6314-20